Lupin Pharmaceuticals Inc has received the nod from USFDA to market generic norethindrone tablets
Drug maker Lupin said it had received the final approval from the US health regulator to market generic version of Watson's Nor-QD tablets, an oral contraceptive, in the American market.
The company's US-based subsidiary, Lupin Pharmaceuticals Inc, has received the nod from US Food and Drug Administration (USFDA) to market generic norethindrone tablets in the strength of 0.35mg, Lupin said in a statement.
Lupin group president and executive director Nilesh Gupta said: "This ANDA approval from the USFDA marks Lupin's foray into the US oral contraceptive market. We look forward to several more approvals and launches in the quarters and years to come.
NOR-QD (norethindrone tablets, USP 0.35mg) is a progestin-only oral contraceptive indicated for the prevention of pregnancy, the company said. "Lupin will commence shipping its norethindrone tablets, USP 0.35 mg shortly," it added.
According to IMS Health sales data for 12 months ended June 2011, the combined annual sales for NOR-QD and its generic equivalents were around $52 million.
On Wednesday, Lupin ended 0.80% up at Rs486.45 on the Bombay Stock Exchange, while the benchmark Sensex declined 0.2% to 17,065.15.
The Revera system would enable LAN to comply with the International Air Transport Association's Simplified Interline Settlement and improve its billing accuracy
Tourism services provider Kale Consultants said that South American airline LAN has selected the company for processing passenger billings. In a filing to the BSE, Kale said that its Revera Interline Service will process passenger billings for LAN.
"We are happy to have LAN as our customer. This engagement is another milestone in our relationship with the airline," said Neela Bhattacharjee, head (airlines), Kale Consultants. The company further said that the Revera system would enable LAN to instantly comply with the International Air Transport Association's (IATA's) Simplified Interline Settlement and improve its billing accuracy. It would also strengthen the cash flows of the airline, the company added.
On Wednesday, Kale ended 5.48% up at Rs90.50 on the Bombay Stock Exchange, while the benchmark Sensex declined 0.2% to 17,065.15.
RDB Rasayans aims to raise Rs32.4-Rs35.55 crore through the issue
Packaging material manufacturer RDB Rasayans is entering capital market with a public issue of 45 lakh equity shares on 21st September and has fixed a price band for the issue at Rs72-Rs79 per equity share.
The company aims to raise Rs32.4-Rs35.55 crore through the issue, which will close on 23 September 2011. The issue would constitute 25.40% of the fully diluted post issue paid up capital of the company, RDB Rasayans said in a statement.
The company proposes to utilise the net proceeds of the issue to finance the capital expenditure to enhance its production facilities, and meeting general corporate purposes. Chartered Capital And Investment Ltd is the sole book running lead manager for the issue.
RDB Rasayans is engaged in the manufacturing of packaging material such as PP Tape, PP woven sacks, woven fabrics, industrial woven fabric, PP woven fabrics and PP woven bags.